The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Leukemia Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
The global Leukemia Therapeutics market size is expected to reach US$ 12890 million by 2029, growing at a CAGR of 2.4% from 2023 to 2029. The market is mainly driven by the significant applications of Leukemia Therapeutics in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Leukemia Therapeutics market. Gleevec, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Sprycel segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Leukemia Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Leukemia Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Leukemia Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Leukemia Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Leukemia Therapeutics covered in this report include Roche, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Eisai, Biogen Idec, ERYtech Pharma, Celgene and Genmab, etc.
The global Leukemia Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
GlaxoSmithKline
Novartis
Bristol-Myers Squibb
Eisai
Biogen Idec
ERYtech Pharma
Celgene
Genmab
Cephalon
Clavis Pharma
Pfizer
Global Leukemia Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Leukemia Therapeutics market, Segment by Type:
Gleevec
Sprycel
Tasigna
Clolar
Others
Global Leukemia Therapeutics market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Leukemia Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Leukemia Therapeutics market size is expected to reach US$ 12890 million by 2029, growing at a CAGR of 2.4% from 2023 to 2029. The market is mainly driven by the significant applications of Leukemia Therapeutics in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Leukemia Therapeutics market. Gleevec, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Sprycel segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Leukemia Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Leukemia Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Leukemia Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Leukemia Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Leukemia Therapeutics covered in this report include Roche, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Eisai, Biogen Idec, ERYtech Pharma, Celgene and Genmab, etc.
The global Leukemia Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
GlaxoSmithKline
Novartis
Bristol-Myers Squibb
Eisai
Biogen Idec
ERYtech Pharma
Celgene
Genmab
Cephalon
Clavis Pharma
Pfizer
Global Leukemia Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Leukemia Therapeutics market, Segment by Type:
Gleevec
Sprycel
Tasigna
Clolar
Others
Global Leukemia Therapeutics market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Leukemia Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Leukemia Therapeutics
1.1 Leukemia Therapeutics Market Overview
1.1.1 Leukemia Therapeutics Product Scope
1.1.2 Leukemia Therapeutics Market Status and Outlook
1.2 Global Leukemia Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Leukemia Therapeutics Market Size by Region (2018-2029)
1.4 Global Leukemia Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Leukemia Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Leukemia Therapeutics Market Size (2018-2029)
1.6.1 North America Leukemia Therapeutics Market Size (2018-2029)
1.6.2 Europe Leukemia Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Leukemia Therapeutics Market Size (2018-2029)
1.6.4 Latin America Leukemia Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Leukemia Therapeutics Market Size (2018-2029)
2 Leukemia Therapeutics Market by Type
2.1 Introduction
2.1.1 Gleevec
2.1.2 Sprycel
2.1.3 Tasigna
2.1.4 Clolar
2.1.5 Others
2.2 Global Leukemia Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Leukemia Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Leukemia Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Leukemia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Leukemia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Leukemia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Leukemia Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Leukemia Therapeutics Revenue Breakdown by Type (2018-2029)
3 Leukemia Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.2 Global Leukemia Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Leukemia Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Leukemia Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Leukemia Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Leukemia Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Leukemia Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Leukemia Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Leukemia Therapeutics Revenue Breakdown by Application (2018-2029)
4 Leukemia Therapeutics Competition Analysis by Players
4.1 Global Leukemia Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Leukemia Therapeutics as of 2022)
4.3 Date of Key Players Enter into Leukemia Therapeutics Market
4.4 Global Top Players Leukemia Therapeutics Headquarters and Area Served
4.5 Key Players Leukemia Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Leukemia Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche Leukemia Therapeutics Products, Services and Solutions
5.1.4 Roche Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Roche Recent Developments
5.2 GlaxoSmithKline
5.2.1 GlaxoSmithKline Profile
5.2.2 GlaxoSmithKline Main Business
5.2.3 GlaxoSmithKline Leukemia Therapeutics Products, Services and Solutions
5.2.4 GlaxoSmithKline Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 GlaxoSmithKline Recent Developments
5.3 Novartis
5.3.1 Novartis Profile
5.3.2 Novartis Main Business
5.3.3 Novartis Leukemia Therapeutics Products, Services and Solutions
5.3.4 Novartis Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Bristol-Myers Squibb Recent Developments
5.4 Bristol-Myers Squibb
5.4.1 Bristol-Myers Squibb Profile
5.4.2 Bristol-Myers Squibb Main Business
5.4.3 Bristol-Myers Squibb Leukemia Therapeutics Products, Services and Solutions
5.4.4 Bristol-Myers Squibb Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Bristol-Myers Squibb Recent Developments
5.5 Eisai
5.5.1 Eisai Profile
5.5.2 Eisai Main Business
5.5.3 Eisai Leukemia Therapeutics Products, Services and Solutions
5.5.4 Eisai Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Eisai Recent Developments
5.6 Biogen Idec
5.6.1 Biogen Idec Profile
5.6.2 Biogen Idec Main Business
5.6.3 Biogen Idec Leukemia Therapeutics Products, Services and Solutions
5.6.4 Biogen Idec Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Biogen Idec Recent Developments
5.7 ERYtech Pharma
5.7.1 ERYtech Pharma Profile
5.7.2 ERYtech Pharma Main Business
5.7.3 ERYtech Pharma Leukemia Therapeutics Products, Services and Solutions
5.7.4 ERYtech Pharma Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 ERYtech Pharma Recent Developments
5.8 Celgene
5.8.1 Celgene Profile
5.8.2 Celgene Main Business
5.8.3 Celgene Leukemia Therapeutics Products, Services and Solutions
5.8.4 Celgene Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Celgene Recent Developments
5.9 Genmab
5.9.1 Genmab Profile
5.9.2 Genmab Main Business
5.9.3 Genmab Leukemia Therapeutics Products, Services and Solutions
5.9.4 Genmab Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Genmab Recent Developments
5.10 Cephalon
5.10.1 Cephalon Profile
5.10.2 Cephalon Main Business
5.10.3 Cephalon Leukemia Therapeutics Products, Services and Solutions
5.10.4 Cephalon Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Cephalon Recent Developments
5.11 Clavis Pharma
5.11.1 Clavis Pharma Profile
5.11.2 Clavis Pharma Main Business
5.11.3 Clavis Pharma Leukemia Therapeutics Products, Services and Solutions
5.11.4 Clavis Pharma Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Clavis Pharma Recent Developments
5.12 Pfizer
5.12.1 Pfizer Profile
5.12.2 Pfizer Main Business
5.12.3 Pfizer Leukemia Therapeutics Products, Services and Solutions
5.12.4 Pfizer Leukemia Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 Pfizer Recent Developments
6 North America
6.1 North America Leukemia Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Leukemia Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Leukemia Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Leukemia Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Leukemia Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Leukemia Therapeutics Market Dynamics
11.1 Leukemia Therapeutics Industry Trends
11.2 Leukemia Therapeutics Market Drivers
11.3 Leukemia Therapeutics Market Challenges
11.4 Leukemia Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
